Eisai Files Marketing Authorization Application for Lecanemab as Treatment For Early Alzheimer’s Disease in South Korea
TOKYO and CAMBRIDGE, Mass., Jun 8, 2023 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that Eisai has submitted a marketing authorization […]